For decades, eye doctors have relied on standard vision charts to measure whether treatments work, but these tests often miss the real-world improvements that matter most to patients with severe vision loss. A new peer-reviewed study published in Documenta Ophthalmologica shows that a performance-based vision test called the Multi-luminance Shape Discrimination Test (MLSDT) can reliably capture how patients with severe retinal disease actually navigate their daily lives. The research comes at a critical moment in ophthalmology. Nanoscope Therapeutics, a biotechnology company developing vision-restoring treatments, conducted a prospective observational study involving 35 participants, including 25 people with severe vision loss from retinitis pigmentosa (RP) and 10 with normal vision. The findings provide strong evidence that MLSDT is a valid and reliable way to measure functional vision in individuals with severe visual impairment. Why Standard Vision Tests Fall Short for Severe Vision Loss? Best-corrected visual acuity (BCVA), measured using traditional eye charts, has been the gold standard in ophthalmology for generations. However, this approach has a significant limitation: it doesn't capture how patients actually function in real-world settings. Someone with severe vision loss might score poorly on a standard chart but still experience meaningful improvements in their ability to move around, recognize objects, or perform daily tasks. Retinitis pigmentosa is a progressive genetic disorder that causes the light-sensitive cells in the retina to deteriorate over time, leading to severe vision loss and blindness. For patients with this condition, traditional vision testing often fails to reflect the subtle but life-changing improvements that new therapies might provide. This gap between test results and real-world function has made it difficult for doctors and patients to understand whether new treatments are truly working. "While best-corrected visual acuity has long been the gold standard in ophthalmology, it can be supplemented with new ways to assess how patients with severe vision loss navigate their daily lives," explained Samarendra Mohanty, Chief Scientific Officer at Nanoscope Therapeutics. Samarendra Mohanty, Chief Scientific Officer at Nanoscope Therapeutics What Does the MLSDT Actually Measure? The Multi-luminance Shape Discrimination Test is a performance-based assessment that evaluates a patient's ability to recognize shapes at different brightness levels. Unlike traditional charts that test static visual acuity, MLSDT measures functional vision by asking patients to identify objects under varying lighting conditions, which more closely mirrors real-world visual challenges. In Nanoscope's RESTORE Phase 2b/3 clinical trial of their lead therapy, MCO-010, researchers used MLSDT as a secondary endpoint alongside traditional BCVA testing. The results were striking: at week 52, the majority of patients treated with MCO-010 improved by 2 or more luminance levels on the MLSDT, representing a clinically meaningful magnitude of improvement. This means patients could recognize shapes at significantly lower brightness levels after treatment, a change that translates to better function in dim environments. How This Changes Treatment Development and Patient Care The validation of MLSDT has important implications for how future vision-restoring therapies are tested and approved. MCO-010 is an optogenetic therapy, a cutting-edge approach that works by activating remaining retinal cells to become light-sensitive after photoreceptor death. The therapy is administered as a one-time, in-office injection without requiring genetic testing or repeat dosing. By incorporating functional vision assessments like MLSDT into clinical trials, researchers can better understand whether treatments actually improve patients' quality of life. This shift toward measuring real-world function represents a significant evolution in how ophthalmology evaluates therapeutic success. Steps for Integrating Functional Vision Testing Into Clinical Practice - Standardized Assessment Tools: Eye care providers can adopt validated functional vision tests like MLSDT alongside traditional visual acuity measurements to capture a more complete picture of patient outcomes. - Patient-Centered Endpoints: Clinical trials for retinal disease treatments should include performance-based assessments that reflect how patients navigate real-world environments, not just how they perform on standard charts. - Collaborative Development: Researchers, clinicians, and patient communities should work together to define what "meaningful improvement" means for people with severe vision loss, ensuring that new therapies address actual patient needs. The peer-reviewed publication of these findings in a Springer Nature journal signals that the ophthalmology community is ready to embrace more sophisticated ways of measuring vision improvement. As more vision-restoring therapies move through clinical development, functional vision assessments will likely become standard practice. "While Nanoscope continues to lead through its development of ground-breaking optogenetic therapies, this observational study shows our commitment to partnering with the retina community on how therapeutic success is measured," stated Samuel Barone, Chief Medical Officer at Nanoscope Therapeutics. Samuel Barone, Chief Medical Officer at Nanoscope Therapeutics For the estimated millions of people living with retinal degenerative diseases like retinitis pigmentosa, Stargardt disease, and geographic atrophy, this shift toward functional vision testing offers hope. It means that future treatments will be evaluated not just on technical improvements to vision charts, but on whether they actually help patients see and function better in their everyday lives. As MCO-010 moves toward potential FDA approval, the validation of MLSDT demonstrates that the field is committed to measuring what truly matters to patients.
